For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) [1987] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening
  • ACR global functional status class of 1 to 3
  • Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
  • All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening
  • Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1)
  • Elevated High-sensitivity (hs) CRP

Exclusion Criteria:

  • Active serious infection
  • History of or active tuberculosis (TB)
  • Elevated liver function tests (LFTs)

Read more: